Conference Presentations
2024 American Association for Cancer Research (AACR) Poster Presentation
Frontline vaccination with the B-cell peptide compound HER-Vaxx (IMU-131), combined with standard-of-care chemotherapy induces high levels of HER2-specific antibodies mediating ADCC and intracellular phosphorylation inhibition resulting in overall survival benefit in patients with HER2+ metastatic or advanced gastric/GEJ adenocarcinoma – Final results from Phase II/HERIZON study (presented by Joshua Tobias Ph.D)
ASX Small and Mid-Cap Conference 2024
Developing Cancer Immunotherapies (presented by Dr Nick Ede)
2024 ASCO Gastrointestinal Cancers Symposium
Oncolytic Virus CF33-hNIS Monotherapy for the Treatment of Gastrointestinal Malignancies (presented by Dr Daneng Li and Grey Wilkinson)
The 8th Oncolytic Virotherapy Summit